Effects of depletion of EPAS1 and knocking down TNFSF10 in 786-O cell lines.

VHL loss leads to the stabilization of hypoxia-inducible factor α (HIFα), which may drive various tumor-promoting pathways. Here, we depletion expression of HIF2α in 786-O and performed transcriptome profiling to assess the molecular impact. TRAIL represents a promising avenue for cancer therapy due to its ability to selectively target and kill tumor cells. However, its effectiveness is variable across different cancer types, even with some tumors exhibiting high levels of TRAIL expression. To investigate this situation, we used shRNA to target TNFSF10, aiming to understand its impact on tumor development. To analyze the differntial gene expression of 786-O kidney cancer cell lines under four different conditions to understand the effect of HIF2α knocking out via CRISPR-Cas9 and TNFSF10 knocking down using inducible shRNA (with and without doxycycline induction for 48 hours). Each condition will have its set of biological replicates to ensure statistical significance.

VHL缺失会导致缺氧诱导因子α（hypoxia-inducible factor α, HIFα）稳定性升高，进而驱动多条促肿瘤信号通路的激活。本研究在786-O细胞中敲低HIF2α的表达，并开展转录组表达谱分析以评估其分子层面的调控效应。肿瘤坏死因子相关凋亡诱导配体（TRAIL）可选择性靶向并杀伤肿瘤细胞，是极具潜力的癌症治疗手段。然而，其临床疗效在不同癌种中存在显著差异，部分肿瘤即便高表达TRAIL亦无法取得理想治疗效果。为探究这一现象，本研究采用短发夹RNA（shRNA）靶向TNFSF10基因，以期阐明其对肿瘤发生发展的调控作用。本研究旨在分析786-O肾癌细胞系在四种不同处理条件下的差异基因表达情况，以明确CRISPR-Cas9介导的HIF2α敲除与诱导型shRNA介导的TNFSF10敲低（分别给予或不给予多西环素诱导48小时）的生物学效应。每组处理均设置生物学重复，以保障实验结果的统计学显著性。